Member Info for goupplease

See more action as America gets cracking

Big Mj such a supporter here ,
Why you guys don't just filter ross and lll is beyond me ,you read their negative rubbish year after year..

Are share holders getting the offer for shares anybody please .
I can't see it yet and nothing from broker

If this heads like sorrell done for wpp .this will be a good investment. .
Nothing much with buys but heading up nicely again

Gone ,nearer a deal ,

Here for 2019 now , this is big....

Wish I had bought more .
Could be share of 2019

Here for 2019 now , this is big

It's a done deal imho , they said avanced discussion.

Hopes pinned on take over here .
It must be well on radar now.

They didn't want this to spike up ,
Kept spread tight and buys where anything over 2.80
Why?

Sorrell

Not much free float ,this could move fast

Playing it down but imho the deals going through this week ,this could be the share of 2019

This is not aim it's the main market
Bod said no raising of money
Was launched at 4p
Get in

This is not aI'm it's the main market
Bod said no raising of money
Was launched at 4p
Get in

NewsSun 19:02WATCH out this week for shares in Nuformix, the small drug developer listed on the main market.

The Cambridge-based company, which counts former Vectura chief executive Chris Blackwell as a director, is set to release the results of a pre-clinical trial for a drug it hopes will treat lung fibrosis, a debilitating condition for which there is currently no cure.

The company takes old drugs cast off by major pharmaceutical companies, works its magic (‘repurposes’ the drug to use the industry term) and then finds a new use for them. In this case, GlaxoSmithKline dumped the drug years ago after a trial flopped.

Nuformix is now developing the drug programme, called NXP002, to target lung fibrosis. In September, the company filed an extra patent for NXP002 so it can be used to treat other fibrotic conditions.

I understand the results of the trial, carried out with the help of Newcastle University using lung tissue from multiple patients, are set to be positive.

Stock watchers should keep an eye on the shares this week which could receive a nice booster from the news.

This share price moving , for me the last rns deserved better , nfx still not where it should be ,
Could not ask for more from bod ,done everything they promised,

WATCH out this week for shares in Nuformix, the small drug developer listed on the main market.

The Cambridge-based company, which counts former Vectura chief executive Chris Blackwell as a director, is set to release the results of a pre-clinical trial for a drug it hopes will treat lung fibrosis, a debilitating condition for which there is currently no cure.

The company takes old drugs cast off by major pharmaceutical companies, works its magic (‘repurposes’ the drug to use the industry term) and then finds a new use for them. In this case, GlaxoSmithKline dumped the drug years ago after a trial flopped.

Nuformix is now developing the drug programme, called NXP002, to target lung fibrosis. In September, the company filed an extra patent for NXP002 so it can be used to treat other fibrotic conditions.

I understand the results of the trial, carried out with the help of Newcastle University using lung tissue from multiple patients, are set to be positive.

Stock watchers should keep an eye on the shares this week which could receive a nice booster from the news.

benchpressmike to see some nice aim tips

You can follow bigmj @benchpressmike

Mike is now one of the stars of aim
Cheers paul